Amplia Therapeutics Ltd

Amplia Therapeutics has a strong liquidity position, with a current ratio of 7.91 and cash and equivalents amounting to AUD 10,863,280. The company's price-to-book ratio is 3.17, indicating that the market value is trading at a premium to its book value. However, the company's return on equity is -0.3126 and return on assets is -0.2865, reflecting a lack of profitability. The company's financial performance is not aligned with typical profitability metrics for the biotechnology and medical research industry. Its operating income and net income are negative, with operating income at -AUD 6,803,980 and net income at -AUD 6,572,030. The company's enterprise value to EBITDA is -8.21, and its enterprise value to revenue is 14.81, both of which are not indicative of a profitable business model. Amplia Therapeutics' revenue is concentrated in a single business line, as it is a clinical-stage company with no commercial products. The company's pipeline includes narmafotinib (AMP945) and AMP886, with narmafotinib in phase 2 clinical trials for pancreatic cancer and in development for ovarian cancer and idiopathic pulmonary fibrosis. The company's geographic exposure is primarily in Australia, with no disclosed international revenue streams. The company's growth trajectory is speculative, as it is in the clinical development stage. The company's revenue is not expected to grow significantly in the near term, as it is not yet generating revenue from commercial products. The company's outlook for the current fiscal year and the next fiscal year is not provided, but the company's operating cash flow is negative at -AUD 6,885,920, and its free cash flow is -AUD 6,488,470. The company's risk assessment indicates low liquidity and dilution risk. There are no immediate filing-based liquidity or dilution flags. The company's debt-to-equity ratio is 0.0, indicating no long-term debt. The company's capital expenditure is minimal at -AUD 2,070, and its long-term debt is only AUD 13,890. Recent events related to Amplia Therapeutics include the ongoing clinical trials for narmafotinib and AMP886. The company's lead drug candidate, narmafotinib, is in phase 2 clinical trials for pancreatic cancer and in development for ovarian cancer and idiopathic pulmonary fibrosis. The company's second pipeline drug, AMP886, is being evaluated in preclinical models of cancer.